Shares of Eli Lilly climbed Thursday after the drugmaker reported third-quarter earnings that blew past expectations. Eli Lilly shares were up 5.6% to $859 in premarket trading Thursday. Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate of $5.4 billion.
Continue Reading
Visualizza commenti
Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal
Published 1 week ago
Oct 30, 2025 at 11:13 AM
Positive
Auto